Table 2. Scenario Analyses.
| Parameter | ICER ($/QALY) |
|---|---|
| Base-case scenario | |
| Long-term OS extrapolated from survival curves35 | 340 409 |
| Pembrolizumab schedule: 200 mg every 3 wk | |
| Time horizon: 3 y | |
| Scenario analysis | |
| Long-term OS estimation | |
| Optimistic scenario: Patients alive after 30 mo were cured of HCC | 222 109 |
| Pembrolizumab schedule | |
| Alternative schedule: 400 mg every 6 wk | 286 884 |
| Time horizon | |
| 5 y | 233 064 |
| 10 y | 197 305 |
| Lifetime | 196 317 |
Abbreviations: HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; OS, overall survival; QALY, quality-adjusted life-year.